Grown Rogue International (GRUSF) Gains from Sales and Divestitures (2018 - 2025)
Grown Rogue International (GRUSF) recorded quarterly Gains from Sales and Divestitures of $26715.0 in Q2 2025, little changed quarter-over-quarter from $26715.0 in Q1 2025, and up 1127.15% on a YoY basis from $2177.0 in Q2 2024.
Grown Rogue International (GRUSF) Gains from Sales and Divestitures (2018 - 2025) Analysis & Trends
Grown Rogue International's Gains from Sales and Divestitures history runs 8 years deep, the most recent figure standing at $26715.0 for Q2 2025.
- In Q2 2025, Gains from Sales and Divestitures rose 1127.15% year-over-year to $26715.0; the TTM figure through Jun 2025 stood at $26715.0 (up 1127.15% YoY), while the FY2023 annual figure was $87699.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $26715.0 for Q2 2025 at Grown Rogue International, roughly flat from $26715.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $168144.0 in Q2 2023 to a low of -$168144.0 in Q1 2023.
- Historically, Gains from Sales and Divestitures has averaged $12717.9 across 5 years, with a median of $6250.0 in 2022.
- Biggest YoY gain for Gains from Sales and Divestitures was 2590.3% in 2023; the steepest drop was 2590.3% in 2023.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $7542.0 in 2021, then retreated by 17.13% to $6250.0 in 2022, then surged by 1303.18% to $87699.0 in 2023, then slumped by 108.92% to -$7823.0 in 2024, then surged by 441.49% to $26715.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $26715.0 (Q2 2025), $26715.0 (Q1 2025), and -$7823.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Grown Rogue International | - | - | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 26,715.00 |
| Jun 30, 2025 | 26,715.00 |
| Mar 31, 2025 | 26,715.00 |
| Mar 31, 2025 | 26,715.00 |
| Sep 30, 2024 | -7,823.00 |
| Sep 30, 2024 | -7,823.00 |
| Jun 30, 2024 | 2,177.00 |
| Jun 30, 2024 | 2,177.00 |
| Mar 31, 2024 | 2,177.00 |
| Mar 31, 2024 | 2,177.00 |
| Dec 31, 2023 | 87,699.00 |
| Dec 31, 2023 | 87,699.00 |
| Oct 31, 2023 | 13,881.00 |
| Oct 31, 2023 | 13,881.00 |
| Apr 30, 2023 | 168,144.00 |
| Apr 30, 2023 | 168,144.00 |
| Jan 31, 2023 | -168,144.00 |
| Jan 31, 2023 | -168,144.00 |
| Oct 31, 2022 | 6,250.00 |
| Oct 31, 2022 | 6,250.00 |